ASX:TLX Telix Pharmaceuticals (TLX) Stock Price, News & Analysis → How’d you do in 2022 (From Brooks Enterprises) (Ad) Free TLX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume746,789 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Telix Pharmaceuticals alerts: Email Address Ad Brooks EnterprisesWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red.Get those kind of results during the Great Financial Crisis, without having to study more About Telix Pharmaceuticals Stock (ASX:TLX)Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More Ad Brooks EnterprisesWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red.Get those kind of results during the Great Financial Crisis, without having to study more TLX Stock News HeadlinesMay 27, 2024 | msn.comWhich ASX biotech shares are pioneering the future of medicine?May 26, 2024 | finance.yahoo.comTelix Submits NDA for New Prostate Cancer Imaging AgentMay 21, 2024 | msn.comASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battleMay 20, 2024 | finance.yahoo.comTelix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate CancerMay 17, 2024 | msn.comTelix, Australian radiopharmaceuticals maker, files for $100M US IPOMay 3, 2024 | msn.comTwo high-flying ASX shares: One upgraded, one downgradedMay 1, 2024 | msn.comBacked by industry titans, this fundie is leveraging Australia's healthcare innovationApril 25, 2024 | msn.comUp 74% in 6 months, guess which ASX 200 healthcare stock just hit another all-time highApril 18, 2024 | fool.com.auWhy is the Telix share price jumping 15% to a record high?April 17, 2024 | finanznachrichten.deTelix Pharmaceuticals Limited: Q1 2024 Revenue and Business UpdateApril 17, 2024 | finance.yahoo.comQ1 2024 Revenue and Business UpdateApril 16, 2024 | finance.yahoo.comQSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGERApril 15, 2024 | msn.com'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stockApril 4, 2024 | msn.comWhy Aurelia Metals, Elders, GQG, and Telix shares are storming higher todayMarch 27, 2024 | finance.yahoo.comWorld First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in SpainMarch 12, 2024 | wsj.comTelix Pharmaceuticals Ltd.March 4, 2024 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production PlatformFebruary 22, 2024 | msn.comInaugural profit overlooked as R&D spending soars at Telix PharmaceuticalsFebruary 22, 2024 | finance.yahoo.comTelix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage PipelineFebruary 8, 2024 | finanznachrichten.deQSAM Biosciences Inc.: QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix PharmaceuticalsFebruary 7, 2024 | finance.yahoo.comTelix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting PlatformFebruary 7, 2024 | finance.yahoo.comQSAM Biosciences Signs Definitive Agreement to be Acquired by Telix PharmaceuticalsFebruary 2, 2024 | fool.com.au2 top ASX growth shares to buy right now and hold for the long termJanuary 22, 2024 | finance.yahoo.comTelix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)January 4, 2024 | finance.yahoo.comTelix Announces Planned Registered Public Offering and Listing in the United StatesSee More Headlines Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:TLX CUSIPN/A CIKN/A Webwww.telixpharma.com Phone61 4 4914 8448FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.02 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.21 million Net Margins1.04% Pretax MarginN/A Return on Equity4.55% Return on Assets9.92% Debt Debt-to-Equity Ratio11.72 Current Ratio1.43 Quick Ratio3.00 Sales & Book Value Annual Sales$502.55 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.35 Book ValueA$0.46 per share Price / BookN/AMiscellaneous Outstanding Shares334,130,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.31 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Christian P. Behrenbruch BEng(Hons) (Age 48)DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Executive Director Comp: $669.24kMr. Darren Smith B.Bus. (Age 59)FCPA, M.B.A., Group Chief Financial Officer Comp: $571.17kDr. Andreas Kluge M.D. (Age 59)Ph.D., Chief Medical Advisor & Non-Executive Director Comp: $43kMr. Richard Valeix M.B.A. (Age 49)Group Chief Commercial Officer Comp: $638.49kMr. Darren Patti (Age 52)Group Chief Operating Officer Dr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.Group General CounselMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersChristian BehrenbruchSold 153,298 sharesTotal: $1.69 M ($11.00/share) TLX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Telix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS). This page (ASX:TLX) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro| SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.